MYDA Advisors’s Marker Therapeutics MRKR Stock Holding History

MYDA Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6,810	Closed	-$539K	–	136
2019 Q2	$539K	Buy	+6,810	New	+$404K	0.18%	69

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

MYDA Advisors's MRKR Position: Q3 2019 in Review

MYDA Advisors sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 6,800 shares — an estimated $539K sold.

MYDA Advisors first reported a position in MRKR in Q2 2018 and held it in 4 quarters. The position peaked at $548K in Q1 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

MYDA Advisors reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
MYDA Advisors sold 6,800 Marker Therapeutics shares in Q3 2019, an estimated $539K.
MYDA Advisors first reported a position in Marker Therapeutics in Q2 2018 and held it in 4 quarters.
MYDA Advisors's Marker Therapeutics position peaked at $548K in Q1 2019.
73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on MYDA Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.